Aurora Cannabis brought in $81.1 million in net revenue in the three months ending September 30, 2024, and reported a net loss of nearly $13 million in the company’s newest quarterly report. 

Net revenue was up 3% in Q2 2025 from the previous quarter and 29% from the same quarter in 2024. This increase was driven by a 30% and 41% increase in medical cannabis sales, respectively. In the same time frame, non-medical “adult use” cannabis sales dropped 10% and 13%, respectively. 

Medical sales were assisted by strong growth in the international sector. Sales of medical cannabis in Canada were $26.3 million, while sales through international sales channels were $35 million, for a total of $61.3 million. 

Non-medical sales were $10.4 million, while Aurora brought in another $750,000 in wholesale bulk cannabis net revenue. The company also incurred $7.8 million in federal excise tax in the most recently reported three-month period. 

“Our strong quarterly results demonstrate Aurora’s leadership in global medical cannabis and ability to capitalize on opportunities within rapidly growing markets such as Australia, Germany, Poland, and the UK,” said chairman and CEO Miguel Martin in a press release.

“International revenue increased 93% to $35 million, exceeding Canadian Medical revenue for the first time, and contributing 57% to total global medical cannabis revenue. The Bevo plant propagation segment also grew a robust 21% during its seasonally lowest quarter, proving the efficacy of our diversified operating model.”

Just under $15.1 million of Aurora’s international sales were in the Australian market, while $20 million were in Europe and $26.3 million were in Canada.

Aurora’s major subsidies include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, TerraFarma Inc., Whistler Medical Marijuana Corporation, Bevo Agtech Inc., CannaHealth Therapeutics Inc., ACB Captive Insurance Company Inc., Indica Industries Pty Ltd. (MedReleaf Australia).

The cannabis producer reported an increase in the average selling price of indoor cannabis, from $4.88 on March 31, 2024, to $5.74 as of September 30. The weighted average fair value less the cost to complete and the cost to sell a gram of dried cannabis produced at Aurora’s Indoor cannabis cultivation facilities was $4.39 per gram (March 31, 2024 – $3.76 per gram).

Related Articles

Aurora Cannabis receives patent related to autoflower cannabis

September 17, 2024

Aurora and UBC partner on research to breed fruity-smelling cannabis

October 2, 2024

Aurora Cannabis receives additional German licences

July 25, 2024